Get the Stockscreener App
0.00
100.00%
-104.91
Exact Sciences Corp stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$104.91
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$20.03B
Revenue:
$3.25B
Net Income/Loss:
$-207.95M
P/E Ratio:
0.00
EPS:
-1.1046
Net Cash Flow:
$356.78M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$104.98
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
0.00 | 20.03B | 3.25B | -207.95M | 356.78M | -1.1046 |
TMO
Thermo Fisher Scientific Inc
|
491.46 | 182.57B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
191.12 | 135.26B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.55 | 45.24B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.48 | 32.63B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.24 | 29.85B | 3.17B | 642.63M | 516.49M | 10.77 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Mizuho | Outperform → Neutral |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
EXAS Technical Analysis & Stock Price Forecast - Intellectia AI
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now - AD HOC NEWS
EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Exact Sciences Completes Enrollment of DeeP-C Clinical Trial for Colorectal Cancer Screening - yahoo.com
Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026? - AD HOC NEWS
Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History - GuruFocus
Exact Sciences (NASDAQ: EXAS) files Form 15 to suspend certain SEC reporting duties - Stock Titan
Exact Sciences Corp (EXK.DU) stock price, news, quote and history - Yahoo Finance UK
Excelerate Energy Stock: Leading Provider of LNG Infrastructure Faces Evolving Global Energy Demands - AD HOC NEWS
EXAS PE Ratio & Valuation, Is EXAS Overvalued - Intellectia AI
Cinctive Capital Management LP's Exact Sciences Corp(EXAS) Holding History - GuruFocus
Vanguard disaggregates holdings; Exact Sciences (NASDAQ: EXAS) shows 0 shares - Stock Titan
Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences - Insider Monkey
Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update - AD HOC NEWS
Privia Health screening program increases colorectal cancer screening rates - MSN
Abbott (ABT) Stock Completes $21B Exact Sciences (EXAS) Acquisition - CoinCentral
Abbott closes $23 billion deal to buy Madison-based Exact Sciences - Yahoo Finance
EXAS Receives Neutral Rating from BTIG's Mark Massaro | EXAS Sto - GuruFocus
Abbott completes Exact Sciences acquisition - MassDevice
Key facts: Abbott Buys Exact Sciences; Notes Settle $105; Nasdaq Delist - tradingview.com
Exact Sciences Corp stock delisted from Nasdaq after $21 billion Abbott acquisition completion - AD HOC NEWS
Abbott Acquires Exact Sciences to Lead Cancer Screening and Diagnostics Market - Minichart
Exact Sciences Corp (EXAS) Files 8-K Announcing Material Agreements, Amendments, and Supplemental Indentures – March 2026 - Minichart
Abbott completes acquisition of Exact Sciences By Investing.com - Investing.com Canada
Exact Sciences Corp. stock delisted from Nasdaq after $21 billion Abbott acquisition completion - AD HOC NEWS
Abbott completes acquisition of Exact Sciences - Investing.com
Abbott completes $21 billion acquisition of Exact Sciences, delisting EXAS from Nasdaq - Investing.com
Exact Sciences (EXAS) director has equity cancelled and cashed out at $105 per share in Abbott merger - Stock Titan
Abbott’s buyout of Exact Sciences (EXAS) cashes out director’s shares - stocktitan.net
Abbott buys Exact Sciences (NASDAQ: EXAS) in $105-per-share cash merger - Stock Titan
Abbott buyout sees Exact Sciences (EXAS) director surrender all shares - Stock Titan
Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening - intellectia.ai
Exact Sciences Amends Convertible Notes; Post-Merger Conversions Payable in Cash at $105 Per Share - TradingView
Abbott buys Exact Sciences (NASDAQ: EXAS) in $21B cash deal - Stock Titan
Abbott (NYSE: ABT) closes Exact Sciences cancer diagnostics deal - Stock Titan
Exact Sciences Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Exact Sciences Corp. stock faces analyst scrutiny amid moderate buy consensus and growth challenges - AD HOC NEWS
Exact Sciences Corporation (EXAS) Stock Price, News, Quote & History - Yahoo! Finance Canada
How Walgreens’ Pharmacy-Led Cologuard Expansion At Exact Sciences (EXAS) Has Changed Its Investment Story - Yahoo Finance
The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout - simplywall.st
Abbott to close Exact Sciences acquisition on March 23 By Investing.com - Investing.com South Africa
Abbott (NYSE:ABT) Expands Diagnostics With Exact Sciences Amid S&P 500 Futures - Kalkine Media
Exact Sciences and Abbott receive all approvals for planned merger By Investing.com - Investing.com India
Abbott Laboratories to close $21B Exact Sciences deal Monday - Modern Healthcare News
When Abbott Labs expects to close on $23B takeover of Exact Sciences - The Business Journals
Exact Sciences Corp Announces Merger Agreement with Abbott Laboratories – SEC 8-K Filing March 2026 - minichart.com.sg
Abbott to close $21B Exact Sciences acquisition Monday - MedTech Dive
Abbott to close Exact Sciences acquisition on march 23 - Investing.com
Abbott to close Exact Sciences acquisition on March 23 - investing.com
Exact Sciences and Abbott receive all approvals for planned merger - Investing.com
Exact Sciences Nears Completion of Abbott Acquisition Deal - TipRanks
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):